PharmaVentures Divests Manufacturing Facility for Major Pharma Client

OXFORD, UK, July 7th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May, represents a significant success for the major Pharma in implementing its forward strategy and the acquisition of a growth driving capability for the acquirer. This divestment follows multiple divestments of R&D and Manufacturing facilities in the last 4 years for several of the largest pharmaceutical companies.

PharmaVentures expands reach to Latin America

OXFORD, UK, May 21st, 2014

PharmaVentures is pleased to announce the appointment of Latin American expert Valeria Uribe as associate to significantly enhance the global reach of the Corporate Advisory team. 

PharmaVentures engaged in valuation of assets for newly AIM listed Tiziana Life Sciences.

OXFORD, UK, May 12th, 2014

PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it's successful admission onto London Stock Exchange's AIM in April 2014.

Novartis appoints PharmaVentures as advisors on the future of its UK Horsham site

OXFORD, England, April 11th, 2014

PharmaVentures is pleased to announce that it has been appointed by Novartis as advisors on the future options for its UK Horsham site. 

PharmaVentures Strengthens M&A Team

OXFORD, UK, December 12th 2013

PharmaVentures is pleased to announce the appointment of expert industry executive Nigel Trim as an associate to significantly enhance PharmaVentures Corporate Advisory offering to the CRO space. 

PharmaVentures advised Nanosight on its sale to Spectris plc.

OXFORD, UK, September 30th, 2013 

PharmaVentures is pleased to announce that it has acted as exclusive M&A advisor to NanoSight in the successful sale of the company to Malvern Instruments, a Spectris plc company. Malvern completed the acquisition on 30th September 2013.

PharmaVentures advised Dogu Tip on its sale to Gulf Capital

OXFORD, UK, April 11th, 2013

PharmaVentures is pleased to announce that Techno Group Investment Holdings, a portfolio company of Gulf Capital, has acquired 100% of Doğu Tip, a Turkish provider of outsourced diagnostic imaging services, with a subsequent allocation of 25% incentive shares to the management.

PharmaVentures, a leading life science and healthcare advisory firm, was advisor to Doğu Tip and its shareholders.
Techno Group is the leading provider of diagnostic imaging services in the MENA region.  Gulf Capital is a leading MENA private equity firm based in Abu Dhabi with close to $2 billion in assets under management.

PharmaVentures Acts as Exclusive Advisor to Sanofi in the Divestment of Zentiva's Hlovovec Production Facility to Wood Pharma Holding

OXFORD, UK, December 19th, 2012

PharmaVentures is pleased to announce that it has acted as transaction advisors and sale process executioners for Sanofi. The current deal covers Sanofi's divestment of its Zentiva subsidiary's production plant in Hlohovec, Slovakia. Under the terms of this agreement, Sanofi will sell to Wood Pharma Holding the production, packaging and distribution part of its Zentiva business covering Active Pharmaceutical Ingredients (APIs) and Drug Products activities. The sale includes transfer of the production facilities and employees. Future co-operation in the purchase of drug products and APIs produced by Wood Pharma Holding in Hlohovec in the next five years has also been agreed.

Stephen Waterman joins PharmaVentures

Oxford, UK, October 18th, 2012

PharmaVentures today announced the appointment of Stephen Waterman as Vice President in its Corporate Advisory business, significantly enhancing PharmaVentures’ corporate finance capabilities and offerings to the global healthcare and investment communities.

PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund

Oxford, UK, March 21st, 2012

Fintan Walton talks exclusively to Johnson & Johnson (J&J) and GlaxoSmithKline (GSK) about their participation in Index Ventures' latest fund announced today at BIO-Europe Spring in Amsterdam. This €150m fund includes investments from several of Index’s largest existing limited partners and two companies, GSK and the venture capital affiliate of the Janssen pharmaceutical companies of J&J (Janssen).

Pages